Nautilus Biotechnology, Inc., a pharmaceutical company based in the United States, has a ESG score of 25.7, placing it at a medium risk level. The company is focused on developing a platform technology to analyze and understand the human proteome. Nautilus Biotechnology has already created a prototype of their Proteomic Analysis System, a single-molecule instrument.